Figure 7: Impact of pimozide and TOFA combination on CHIKV replication in vitro and in vivo.

(a–c) Infection rate (n=9 for all data sets at increasing concentrations; n=51 for DMSO) (a), supernatant titration (n=8 for all data sets at increasing concentrations; n=57 for DMSO) (b) and cell viability (c) of HEK-293T cells infected with CHIKV-GFP (MOI: 0.5) for 1 h, and then exposed to the indicated concentrations of antiviral drugs for 23 h. Solid and dashed black lines indicate the mean±s.e.m. of the DMSO control (pimo=pimozide). Data in a and c were measured by flow cytometry. (d) Experimental design of the footpad CHIKV infection model of adult mice used to measure the therapeutic effect on CHIKV replication of pimozide, TOFA or their combination (n=13 for all data set, one outlier for pimo is not shown in the graph but was considered for statistics). (e) Footpad swelling measured 4 days post infection in mice treated as in d (n=11, 10, 12 and 12 in displayed order). The experiment shown in e was repeated twice. All the other data were obtained from at least three independent experiments. Data in a,b and c are expressed as the mean±s.e.m. and in d and e are shown as the median±interquartile range; each dot represents one mouse. Statistics were calculated using the Kruskal–Wallis test with the Dunn’s post test (*P<0.05; ^NSP≥0.05) NS, not significant.